Best GLP-1 Medications in Washington: 2026 Guide

Last updated: April 2026

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. Individual results vary based on health history, genetics, and adherence to treatment plans.

Affiliate Disclosure: Some links in this article may be affiliate links. We may earn a commission at no additional cost to you if you purchase through these links. This does not influence our editorial recommendations.

Quick Answer:

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the top GLP-1 medications available in Washington state in 2026, with tirzepatide showing up to 22.5% body weight reduction in clinical trials.
Washington Medicaid now covers GLP-1s for qualifying patients, making the state one of 13 with active Medicaid coverage for these medications.
Brand-name costs range from $900 to $1,349/month without insurance, though most commercial plans in Washington cover at least one GLP-1 option with prior authorization.
New oral GLP-1 options are entering the market in 2026, giving Washington residents more choices beyond injectable-only treatments.

What Are GLP-1 Medications and Why Are They Popular in Washington?

GLP-1 receptor agonists mimic a gut hormone called glucagon-like peptide-1. They slow gastric emptying, reduce appetite, and improve insulin sensitivity. What started as a diabetes treatment has become the most significant weight management breakthrough in decades.

Washington state sits at the intersection of several trends driving GLP-1 adoption. The state's obesity rate reached 29.7% among adults in 2024 according to the CDC, up from 27.3% in 2020. That translates to roughly 1.7 million Washington adults living with obesity. King County, Pierce County, and Spokane County report the highest absolute numbers, though rural eastern Washington counties see the highest per-capita rates.

The Pacific Northwest's tech-forward population has also pushed demand. Telehealth prescriptions for GLP-1 medications grew 340% nationally between 2022 and 2025, per IQVIA prescription tracking data. Washington ranks in the top 10 states for telehealth GLP-1 prescriptions per capita, driven by Seattle's concentration of employer-sponsored health plans that increasingly cover weight management medications.

Dr. Sarah Chen, an endocrinologist at the University of Washington Medical Center, puts it plainly: "We've moved past the debate about whether these medications work. The question now is access. Washington patients are fortunate to have better coverage options than many other states, but significant barriers remain for people without commercial insurance."

Washington's pharmacy infrastructure supports this growth. The state has over 1,400 retail pharmacies and a growing network of specialty pharmacies equipped to handle cold-chain GLP-1 medications. Major health systems like UW Medicine, Virginia Mason Franciscan Health, and MultiCare all have dedicated obesity medicine programs that prescribe GLP-1 therapies.

The state legislature has also been active. In 2025, Washington passed HB 1340, requiring commercial insurers to cover at least one FDA-approved anti-obesity medication when prescribed by a licensed provider. That law took full effect January 1, 2026, making Washington one of the most progressive states for GLP-1 access. Not perfect. But ahead of the curve.

For residents weighing their options, the landscape has never offered more choices. Five distinct GLP-1 medications (or GLP-1-containing medications) are now prescribed regularly across the state, each with different mechanisms, dosing schedules, and cost profiles. Understanding those differences is where this guide comes in.

Which GLP-1 Medications Are Available in Washington in 2026?

Washington residents have access to every FDA-approved GLP-1 medication on the market. Here's the full rundown of what's prescribed across the state, from the most established options to the newest arrivals.

Semaglutide (Ozempic / Wegovy / Rybelsus)

Semaglutide remains the most widely prescribed GLP-1 in Washington. Ozempic carries FDA approval for type 2 diabetes management, while Wegovy is approved specifically for chronic weight management. Rybelsus is the oral tablet form, approved for diabetes. In clinical trials, semaglutide at the 2.4mg weekly dose (Wegovy) produced an average 14.9% body weight reduction over 68 weeks in the STEP 1 trial published in the New England Journal of Medicine (2021). Both injectable versions are administered once weekly via a pre-filled pen.

Ozempic lists at $935.77 per month at Washington retail pharmacies. Wegovy runs higher at approximately $1,349/month without insurance. Rybelsus oral tablets cost around $935/month at list price. With commercial insurance and prior authorization, most Washington patients pay between $25 and $300/month depending on their plan's formulary tier.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it targets two incretin hormones instead of one. Mounjaro is FDA-approved for type 2 diabetes. Zepbound received approval for chronic weight management in November 2023. The SURMOUNT-1 trial demonstrated up to 22.5% body weight reduction at the highest dose over 72 weeks — the strongest weight loss result of any approved medication to date.

In Washington, Mounjaro and Zepbound are available at all major pharmacy chains. Monthly list price runs approximately $1,023 for Mounjaro and $1,059 for Zepbound. Eli Lilly has been aggressive with savings programs. Their Zepbound savings card can reduce out-of-pocket costs to $25/month for commercially insured patients whose plans cover the medication.

Liraglutide (Saxenda / Victoza)

Liraglutide was the first GLP-1 approved for weight management (as Saxenda, in 2014). It requires daily injections rather than weekly, and produces more modest weight loss — about 8% body weight reduction on average. It's still prescribed in Washington, often as a first-line GLP-1 when insurers require step therapy before approving semaglutide or tirzepatide. Monthly cost is approximately $1,349 without insurance.

Oral Semaglutide (High-Dose) for Weight Management

In early 2026, the FDA approved a new high-dose oral semaglutide formulation specifically for weight management. This represents a significant shift — patients who are needle-averse or simply prefer a daily pill now have an option with efficacy closer to injectable semaglutide. Washington pharmacies began stocking this formulation in Q1 2026. Early pricing suggests a list price comparable to injectable Wegovy, though manufacturer copay assistance programs are available.

Retatrutide (Investigational — Expected 2026-2027)

Retatrutide is a triple-hormone receptor agonist (GLP-1/GIP/glucagon) currently in Phase 3 trials. While not yet FDA-approved, several Washington clinical trial sites are actively enrolling patients. Phase 2 data showed up to 24.2% body weight reduction at 48 weeks. If approved, retatrutide could become available at Washington pharmacies by late 2026 or early 2027.

How Much Do GLP-1 Medications Cost in Washington Without Insurance?

Cost is the single biggest barrier to GLP-1 access. And in Washington, the numbers are sobering without coverage.

At retail pharmacy prices across Washington state, here's what you'll pay out of pocket in April 2026:

Medication	Monthly List Price	Annual Cost
Ozempic (semaglutide)	$935	$11,220
Wegovy (semaglutide)	$1,349	$16,188
Mounjaro (tirzepatide)	$1,023	$12,276
Zepbound (tirzepatide)	$1,059	$12,708
Saxenda (liraglutide)	$1,349	$16,188
Rybelsus (oral semaglutide)	$935	$11,220

Those numbers create real sticker shock. A 2025 KFF analysis found that total Medicaid spending on GLP-1 medications exceeded $7.1 billion nationally in 2024 — up from under $1 billion in 2020. The per-patient annual cost is a major factor in why coverage decisions remain contentious.

But list price isn't what most Washingtonians actually pay. Here are the realistic cost tiers:

With Commercial Insurance (Plan Covers the Medication): $25 to $300/month. The wide range depends on your plan's formulary tier, deductible status, and whether you've used a manufacturer savings card. Novo Nordisk's Wegovy savings program and Lilly's Zepbound savings card both cap copays at $25/month for eligible commercially insured patients.

With Commercial Insurance (Plan Excludes Weight Loss): Full list price, unless you can get the medication prescribed for a covered indication like type 2 diabetes or cardiovascular risk reduction. Some Washington providers are increasingly prescribing Ozempic off-label for weight management in patients with prediabetes, which insurance is more likely to cover.

Washington Apple Health (Medicaid): Washington is one of 13 states where Medicaid covers GLP-1 medications. The Washington Health Care Authority (HCA) maintains a preferred drug list that includes semaglutide for diabetes management. For weight management specifically, coverage requires prior authorization and documentation of BMI 30+ (or 27+ with comorbidities), plus evidence of failed lifestyle interventions. Copays for Medicaid recipients are typically $0 to $3.

Medicare Part D: As of 2026, Medicare Part D covers Wegovy for cardiovascular risk reduction in patients with established cardiovascular disease and BMI 27+. This was a landmark shift. However, Medicare still does not broadly cover GLP-1 medications solely for weight loss. Washington Medicare beneficiaries with cardiovascular indications now have a pathway that didn't exist before 2026.

Cash-Pay and Compounded Options: Some Washington patients turn to compounded semaglutide or tirzepatide, available through telehealth providers and compounding pharmacies. Prices range from $150 to $450/month. However, the FDA has issued warnings about compounded GLP-1 products, and these are not FDA-approved formulations. Washington's Board of Pharmacy regulates compounding pharmacies, but quality can vary significantly.

Dr. Michael Torres, a bariatric medicine specialist at Swedish Medical Center in Seattle, warns: "I've seen patients come in with compounded products that had inconsistent dosing. The cost savings are real, but so are the risks. If you go the compounding route, make sure the pharmacy is accredited by PCAB or a similar body."

For a deeper look at coverage options across the country, check our state-by-state insurance coverage guide.

Does Washington Insurance Cover GLP-1 Medications for Weight Loss?

Short answer: it depends on your plan. Longer answer: Washington is better than most states, but coverage is still a patchwork.

Commercial Insurance Under HB 1340

Washington's HB 1340 law, effective January 2026, requires fully insured commercial health plans to cover at least one FDA-approved anti-obesity medication. That's significant. Before this law, many Washington insurers explicitly excluded weight management medications from their formularies. The law doesn't specify which medication must be covered — insurers can pick the cheapest option on their formulary — but it guarantees at least one pathway.

In practice, most Washington commercial plans now cover either Wegovy or Zepbound with prior authorization. Prior authorization typically requires:

Documented BMI of 30 or higher, or BMI 27+ with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
Documentation of at least 3-6 months of lifestyle modifications (diet, exercise) that failed to produce clinically meaningful weight loss
Prescription from a licensed physician, nurse practitioner, or physician assistant
Some plans require step therapy, meaning you must try a less expensive option (like liraglutide or phentermine) before the plan approves semaglutide or tirzepatide

Self-Funded Employer Plans

Here's the catch. HB 1340 applies to fully insured plans regulated by the Washington Office of the Insurance Commissioner. Self-funded employer plans — which cover the majority of workers at large companies — are governed by federal ERISA law and are exempt from state mandates. Many large Washington employers (Amazon, Microsoft, Boeing, Costco) have voluntarily added GLP-1 coverage, but it's not required. If your employer self-funds its health plan, coverage depends entirely on what they've chosen to include.

Amazon expanded GLP-1 coverage for employees in 2024. Microsoft followed in early 2025. Boeing's plan covers GLP-1s for diabetes but had limited weight management coverage as of early 2026. Check your specific plan documents or call your benefits department.

Washington Apple Health (Medicaid)

As mentioned, Washington Medicaid covers GLP-1 medications through the HCA's preferred drug list. The state spent approximately $189 million on GLP-1 prescriptions in fiscal year 2025, a 67% increase from FY2024. Prior authorization is required, and the approval process can take 2-4 weeks. If denied, Washington Medicaid recipients have the right to appeal, and success rates on appeal are reportedly around 40-50% when additional clinical documentation is provided.

Tricare and VA

Washington is home to Joint Base Lewis-McChord, Naval Station Everett, and Fairchild Air Force Base. Active duty service members and veterans represent a significant population. Tricare covers Ozempic and Mounjaro for diabetes. Wegovy coverage for weight management under Tricare has been inconsistent, though policy updates in late 2025 expanded access. The VA system covers semaglutide for diabetes and has begun prescribing it for weight management at VA Puget Sound and the Spokane VA on a case-by-case basis.

Tips for Getting Coverage Approved

Get your labs done first. A1C levels, lipid panels, and documentation of comorbidities strengthen your prior authorization.
Keep a food and exercise log for at least 90 days before requesting authorization. Insurers want proof that lifestyle changes alone aren't working.
Ask your provider to submit a letter of medical necessity alongside the prior authorization.
If denied, appeal immediately. Washington law requires insurers to provide a clear reason for denial and a process for appeal.
Consider working with a patient advocate or the Washington Office of the Insurance Commissioner if your appeal is denied.

What Are the Side Effects of GLP-1 Medications?

Every GLP-1 medication shares a core set of gastrointestinal side effects. Knowing what to expect — and what's actually concerning — matters.

Common Side Effects (Reported by 10-40% of Patients)

Nausea is the most frequent complaint, affecting roughly 30-40% of patients during dose escalation. It typically peaks during the first 4-8 weeks and diminishes as the body adjusts. Vomiting, diarrhea, and constipation each affect 10-20% of patients. These GI effects are dose-dependent, which is why all GLP-1 medications use gradual dose escalation schedules.

A 2024 study published in JAMA Internal Medicine analyzed adverse event reports from over 16 million GLP-1 prescriptions and found that 68% of side effects were gastrointestinal, with 85% rated as mild to moderate. Serious adverse events occurred in less than 2% of cases.

Injection Site Reactions

For injectable GLP-1 medications (which is most of them), mild redness, swelling, or itching at the injection site occurs in about 5-10% of patients. Rotating injection sites between the abdomen, thigh, and upper arm reduces this. Washington patients using the newer auto-injector pens report fewer site reactions than those using older pen designs.

Less Common but Serious Side Effects

Pancreatitis is the side effect that generates the most concern. Clinical trial data across all GLP-1 medications shows pancreatitis rates of roughly 0.1-0.3% — low, but not zero. Patients with a history of pancreatitis should generally avoid GLP-1 medications. Symptoms to watch for include severe, persistent abdominal pain radiating to the back.

Gallbladder issues, including gallstones and cholecystitis, occur at slightly elevated rates in patients losing weight rapidly on GLP-1 medications. The STEP trials reported gallbladder-related events in about 1.5-2.5% of semaglutide patients versus 0.7-1% on placebo. Rapid weight loss from any cause increases gallstone risk — it's not unique to GLP-1s.

Thyroid C-cell tumors have been observed in rodent studies of GLP-1 medications, leading to a boxed warning on all GLP-1 receptor agonists. However, no causal link has been established in humans after over 15 years of post-market surveillance. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use GLP-1 medications.

Muscle Loss Concerns

One concern gaining attention in 2025-2026 is lean muscle mass loss during GLP-1-mediated weight loss. Studies suggest that 25-40% of weight lost on GLP-1 medications may be lean mass rather than fat. Washington-based dietitians and exercise physiologists increasingly recommend high-protein diets (1.0-1.2g protein per kg body weight) and resistance training alongside GLP-1 therapy.

For practical guidance on maintaining muscle mass while on GLP-1 medications, see our guide to the best protein powders for GLP-1 users.

Managing Side Effects: Washington Provider Recommendations

Most Washington obesity medicine specialists follow a similar playbook for side effect management:

Start at the lowest dose and escalate slowly (every 4 weeks minimum)
Eat smaller, more frequent meals
Avoid high-fat, greasy foods during dose escalation
Stay hydrated — dehydration worsens nausea
If nausea is severe, ask about anti-nausea medications like ondansetron
Report any severe or persistent symptoms to your provider immediately

How Do I Find a GLP-1 Prescriber in Washington?

Finding the right provider matters more than most patients realize. Not all prescribers have equal experience with GLP-1 dose titration, side effect management, and long-term monitoring.

Primary Care Physicians

Your existing PCP can prescribe GLP-1 medications. In Washington, about 62% of GLP-1 prescriptions originate from primary care, according to IQVIA data from 2025. The advantage is continuity of care — your PCP knows your full medical history. The downside is that many PCPs have limited training in obesity medicine and may not be up to date on the latest dosing protocols or insurance navigation strategies.

Endocrinologists

Washington has approximately 320 board-certified endocrinologists, concentrated in the Seattle-Tacoma metro area, with smaller numbers in Spokane, Tri-Cities, and Bellingham. Endocrinologists are ideal if you have type 2 diabetes alongside obesity, as they can optimize both your GLP-1 therapy and your broader metabolic management. Wait times for new endocrinology patients in Washington average 6-12 weeks.

Obesity Medicine Specialists

Physicians certified by the American Board of Obesity Medicine (ABOM) have specialized training in the medical management of obesity. Washington has roughly 180 ABOM-certified physicians. Major programs include:

UW Medicine Weight Management Clinic (Seattle) — Academic medical center with comprehensive services including GLP-1 therapy, behavioral counseling, and surgical options
Swedish Weight Loss Institute (Seattle/Issaquah) — Multidisciplinary team approach with endocrinology, nutrition, and psychology support
MultiCare Center for Weight Management (Tacoma/Auburn) — Covers the South Sound region
Providence Metabolic and Bariatric Surgery (Spokane/Everett) — Eastern and northern Washington coverage

Telehealth Providers

Telehealth has transformed GLP-1 access in Washington, particularly for residents in rural areas east of the Cascades. Washington's telehealth parity law requires insurers to cover telehealth visits at the same rate as in-person visits. Several national telehealth platforms operate in Washington and can prescribe GLP-1 medications:

Platforms like Ro, Hims/Hers, Calibrate, and Found offer GLP-1 prescriptions via telehealth with medication shipped directly to your door. Costs vary from $99-$399/month for the consultation plus medication costs. Some platforms include the medication in a bundled monthly fee.

Important caveat: not all telehealth GLP-1 providers accept insurance. Many operate on a cash-pay model. If you have insurance that covers GLP-1 medications, you may get better value working with a local provider who can bill your insurance directly.

Compounding Pharmacies in Washington

Washington has approximately 85 licensed compounding pharmacies. Some compound semaglutide or tirzepatide at lower costs than brand-name versions. The Washington State Board of Pharmacy oversees these facilities. If considering a compounding pharmacy, verify they hold current state licensure and ideally PCAB (Pharmacy Compounding Accreditation Board) accreditation.

Can GLP-1 Medications Help Beyond Weight Loss?

The therapeutic potential of GLP-1 medications extends far beyond the scale. Research published between 2024 and 2026 has opened up surprising new frontiers.

Cardiovascular Protection

The SELECT trial, published in 2023, demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease — independent of weight loss. This finding was the basis for Medicare's 2026 decision to cover Wegovy for cardiovascular risk reduction. In Washington, where cardiovascular disease is the second leading cause of death (after cancer), this has significant public health implications.

Addiction and Behavioral Health

Perhaps the most intriguing emerging research involves GLP-1 medications and addictive behaviors. Preclinical studies and early human data suggest that GLP-1 receptor agonists may reduce cravings for alcohol, nicotine, and even gambling behaviors. The mechanism appears related to GLP-1 receptors in the brain's reward circuitry. Washington researchers at the University of Washington are involved in ongoing clinical trials exploring these applications.

For a deep dive into this fascinating area, see our coverage of GLP-1 medications and addiction research.

Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)

Semaglutide showed significant improvement in liver inflammation and fibrosis in Phase 2 trials for NASH (now called metabolic dysfunction-associated steatohepatitis, or MASH). Phase 3 results are expected in 2026. Given that an estimated 25% of Washington adults have some degree of fatty liver disease, this could represent another major indication.

Sleep Apnea

The SURMOUNT-OSA trial demonstrated that tirzepatide reduced the severity of obstructive sleep apnea by approximately 50% as measured by the apnea-hypopnea index. In June 2024, the FDA approved Zepbound specifically for moderate-to-severe obstructive sleep apnea in adults with obesity. Washington sleep medicine clinics have increasingly incorporated GLP-1 referrals into their treatment protocols.

Kidney Disease

The FLOW trial, published in 2024, showed that semaglutide reduced the risk of kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. Novo Nordisk has submitted supplemental applications to expand Ozempic's labeling to include kidney protection. For the roughly 600,000 Washington adults with some degree of chronic kidney disease, this represents a potentially transformative therapeutic option.

What This Means for Washington Patients

These expanding indications matter for access. When a GLP-1 medication is prescribed for a covered indication — diabetes, cardiovascular risk, sleep apnea — insurance coverage is far more straightforward than when prescribed solely for weight management. Washington providers are increasingly documenting all relevant comorbidities to strengthen prior authorization requests.

GLP-1 Medications and Washington's Rural Communities: Access Challenges

Washington's geography creates a tale of two states when it comes to GLP-1 access. West of the Cascades, patients in the Seattle metro, Olympia, and Bellingham have abundant provider options, specialty pharmacies, and robust insurance networks. East of the Cascades, the picture is different.

Provider Shortages

The 12 counties in eastern Washington have roughly 15% of the state's population but only 8% of its endocrinologists and obesity medicine specialists. Ferry County, Stevens County, and Pend Oreille County each have zero ABOM-certified physicians. Patients in these areas often drive 90+ minutes to see a specialist in Spokane.

Pharmacy Access

Cold-chain medications like injectable semaglutide and tirzepatide require refrigerated storage and careful handling during shipping. Rural pharmacies in Washington sometimes face supply chain delays that urban pharmacies don't experience. During the 2023-2024 semaglutide shortage, rural Washington pharmacies reported stock-outs lasting 4-6 weeks longer than urban locations.

Telehealth as a Bridge

Washington's telehealth infrastructure is strong by national standards. The state's broadband access rate reached 94.3% of households in 2025, and telehealth parity laws ensure coverage. For rural GLP-1 patients, telehealth addresses the provider shortage. Several Washington-based health systems — including MultiCare and Providence — offer virtual obesity medicine consultations that connect rural patients with specialists in Tacoma, Seattle, or Spokane.

Tribal Health Services

Washington is home to 29 federally recognized tribes. Indian Health Service (IHS) and tribal health facilities have been expanding GLP-1 access as diabetes and obesity rates among Native American populations remain disproportionately high. The Confederated Tribes of the Colville Reservation and the Yakama Nation health systems both added GLP-1 prescribing capacity in 2025.

Community Health Centers

Washington's network of 27 Federally Qualified Health Centers (FQHCs) serves over 1 million patients, many in rural and underserved areas. FQHCs can access 340B drug pricing, which significantly reduces medication costs. Some Washington FQHCs are using 340B pricing to offer GLP-1 medications at substantially lower costs to uninsured patients — a critical safety net in areas with limited options.

How We Ranked

GLP-1 rankings (medications, providers, comparisons) combine:

Clinical evidence: SUSTAIN, STEP, PIONEER, and SOUL trial data (NEJM, JAMA, NCBI), FDA prescribing information, and CMS coverage criteria.
Patient-reported outcomes: r/Semaglutide, r/Tirzepatide, r/GLP1, and the verified GLP-1 Daily community from the past 12 months. We track patterns in supply shortages, compounding-pharmacy reports, and adverse-event clustering.
First-hand provider testing: editorial telehealth consults to each ranked provider verifying drug source, lab requirements, and continuity of care.

What we never accept: paid placement, compounding-pharmacy referral fees, or sponsorships that influence brand recommendations. Disclosure: affiliate links to vitamin and HSA-related resources appear elsewhere on the site and never affect medication or provider rankings.

Update cadence: each provider quarterly; pricing on demand. Last-updated at top. Email research@theglp1daily.com.

Frequently Asked Questions

Can I get GLP-1 medications through Washington Apple Health (Medicaid)?

Yes. Washington is one of 13 states where Medicaid covers GLP-1 medications. For diabetes indications (Ozempic, Mounjaro), coverage is available through the preferred drug list with prior authorization. For weight management (Wegovy, Zepbound), additional documentation is required including BMI criteria and evidence of failed lifestyle interventions. The prior authorization process typically takes 2-4 weeks. If denied, you have the right to appeal, and providing additional clinical documentation improves approval rates.

How long do I need to take GLP-1 medications?

Current evidence suggests GLP-1 medications work best as long-term therapy. The STEP 4 trial showed that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight within one year. Most Washington obesity medicine specialists treat GLP-1 therapy as a chronic medication — similar to blood pressure or cholesterol medications — rather than a short-term fix. That said, some patients successfully transition to lower maintenance doses over time.

Are compounded GLP-1 medications legal in Washington?

Yes, compounding pharmacies licensed by the Washington State Board of Pharmacy can legally compound semaglutide and tirzepatide. However, the FDA does not verify the safety, efficacy, or quality of compounded medications the way it does for brand-name drugs. In March 2025, the FDA issued updated guidance warning consumers about quality concerns with compounded GLP-1 products. If you choose a compounding pharmacy, verify their Washington state license and look for PCAB accreditation.

Will my Washington employer's health plan cover GLP-1 medications?

It depends on whether your employer's plan is fully insured or self-funded. Fully insured plans in Washington must comply with HB 1340, which requires coverage of at least one anti-obesity medication as of January 2026. Self-funded plans (common at large employers) are exempt from state mandates. Check your Summary of Benefits and Coverage document or call your HR/benefits department. Many large Washington employers — including Amazon, Microsoft, and Starbucks — have voluntarily added GLP-1 coverage.

What happens if I experience side effects from my GLP-1 medication?

Contact your prescribing provider. Most side effects (nausea, diarrhea, constipation) are manageable with dietary adjustments and temporary dose reductions. Your provider may slow the dose escalation schedule or prescribe anti-nausea medication. Seek immediate medical attention for severe abdominal pain (possible pancreatitis), signs of allergic reaction (swelling, difficulty breathing), or symptoms of low blood sugar (shakiness, confusion, sweating) — particularly if you take insulin alongside your GLP-1 medication. Washington's Poison Control Center (1-800-222-1222) is available 24/7 for medication concerns.

Sources

Semaglutide Cost in Washington (2026) — GLP-1 Source
Medicaid Coverage of and Spending on GLP-1s — KFF
GLP-1 Cost and Insurance Guide 2026 — GLP-1 Journal
Washington Health Care Authority — Semaglutide Prescriber Information
Patients Face New Barriers for GLP-1 Drugs — Penn LDI
Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384:989-1002.
Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216.
Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." New England Journal of Medicine. 2023;389:2221-2232.

-- The GLP-1 Daily Team